Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Development of an analytics dashboard to measure infusion treatment initiation timelines.

Tulsi Patel, Robert Eugene Bernadelli, Adam Burgoyne et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23250

e23250 Background: Prior studies demonstrate that longer time from cancer diagnosis to treatment initiation is associated...

Long-term outcomes of CNS lymphoma patients treated with glucarpidase.

Lauren Webb, Mina Lobbous, Lisa Marie DeAngelis et al. Jun 01, 2026 pp. 2091-2091 10.1200/jco.2026.44.16_suppl.2091

2091 Background: High-dose methotrexate (HD-MTX) is the backbone of potentially curative therapy for central nervous syste...

Impact of social vulnerability on end-of-life care in hematologic malignancies.

Jude O. Ossai, Yazmin Reategui-Almonacid, Oladayo Oyebanji et al. Jun 01, 2026 pp. 12036-12036 10.1200/jco.2026.44.16_suppl.12036

12036 Background: Patients with hematologic malignancies frequently receive intensive inpatient care near theend of life....

Real-world experience with neoadjuvant chemoimmunotherapy in resectable NSCLC: A single academic institution experience.

Marko Jakopovic, Lidija Ljubicic, Lela Bitar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20074

e20074 Background: Neoadjuvant chemoimmunotherapy has led to significant improvements in outcomes for patients with resect...

A pilot study of autologous tumor-infiltrating lymphocytes (LN-145) in adult patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma.

Lauren Baker Banks, Evan Rosenbaum, Edmund Bartlett et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23566

e23566 Background: Advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLS) are difficu...

National trends in inpatient incidence of head and neck cancer and anatomic subsites in the United States, 2018 to 2022.

Sandhya Upreti, Aishwarya Hanspal, Erij Makhdoom et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23233

e23233 Background: Inpatient hospitalizations for head and neck cancer (HNC) reflect severe disease, treatment-related com...

A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).

Alexander I. Spira, David Sommerhalder, Annie Winterhall et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3678

TPS3678 Background: Advanced and metastatic colorectal cancer (CRC) remains an area of significant unmet clinical need, pa...

Integrating interventional radiology into melanoma care: A quality improvement initiative to advance intratumoral therapies and multidisciplinary collaboration.

Gino Kim In, Peter Park, Samuel Dooyema et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23312

e23312 Background: Despite advances in immunotherapy (IO), management of advanced melanoma after anti-PD-1 progression rem...

Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive/MHC-II negative locally advanced GC/GEJC: A prospective, randomized, open-label, biomarker-driven, phase 2 trial.

Xiangdong Cheng, Zhiyuan Xu, Can Hu Jun 01, 2026 pp. 2513-2513 10.1200/jco.2026.44.16_suppl.2513

2513 Background: Neoadjuvant immunotherapy achieves major pathologic response (mPR) in 40% of locally advanced gastric can...

Early-onset colorectal cancer: 2-year analyses of Georgian cancer registry.

Tamar Esakia, Marina Maglakelidze, Davit Kvaratskhelia et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15645

e15645 Background: Incidence of early onset colorectal cancer (EOCRC) is rising. Young patients (age < 50) are often di...

Provider insights and utilization of psychiatric pharmacogenomics for patients with comorbid breast cancer and emotional distress.

Kadie Harry, Kelly C. Gast, Lindsay Leuthen Peterson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24103

e24103 Background: Patients with breast cancer frequently experience anxiety and depression, yet systemic delays in psychi...

Decoding cancers of unknown primary through genomics-driven clustering: A pan-cancer framework for prognostic classification using AACR GENIE data.

Bayan Abu Alragheb, Semiha Ozgul, Mostafa I.H. Ali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15006

e15006 Background: Cancer of unknown primary (CUP) is a heterogeneous metastatic entity lacking an identifiable tissue of...

Early implementation of a lung cancer screening program in a safety-net health system.

Konstantin Kecman, Danielle Luskind, David Smith et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22524

e22524 Background: Lung cancer screening (LCS) with low-dose CT reduces lung cancer mortality but remains underutilized in...

Utilization of risk-reducing interventions among breast cancer patients with pathogenic germline variants across safety-net and academic hospitals.

Aliya Lackan, Samantha Sarlin, Kevin Hoffman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22546

e22546 Background: Risk-reducing interventions (RRI) reduce cancer risk for patients with pathogenic/likely pathogenic ger...

A sponsor-held platform IND model for personalized immunotherapy.

Julianna Lisziewicz, Andras Szasz, Tamas Kos et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23044

e23044 Background: Despite strong biological rationale, personalized cancer immunotherapies have struggled to scale beyond...

Perioperative chemotherapy or preoperative chemoradiotherapy in patients with esophageal carcinoma: A systematic review and meta-analysis.

Shivani Saravanan, Tanmayee Mareedu, Paulami Deshmukh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16105

e16105 Background: Despite advances in treatment options, esophageal carcinoma remains a disease with poor prognosis with...

Neo-adjuvant radiation and intratumoral immunotherapy followed by surgery: The NARIS trial for extremity soft tissue sarcoma.

Rutian Li, Yuchen Ge, Wang Xiaolu et al. Jun 01, 2026 pp. 11566-11566 10.1200/jco.2026.44.16_suppl.11566

11566 Background: Patients with STS who failed to respond to standard treatment have limited subsequent treatment options....

Chemoradiotherapy plus sintilimab versus chemoradiotherapy as neoadjuvant treatment in locally advanced esophageal squamous cell carcinoma (NEOCRTEC2101): A multicenter, randomized, phase III trial.

Mian Xi, Qiaoqiao Li, Qian-Wen Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4248

TPS4248 Background: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is the current standard of care for resectabl...

Impact of prior immune checkpoint inhibition on the clinical efficacy of belzutifan in advanced renal cell carcinoma.

Vedant Shah, Ansy Patel, Pragya Jain et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16547

e16547 Background: Hypoxia-inducible factor 2α (HIF-2α) is a transcription factor that plays a central role in the pathoge...

A prospective study of mpMRI-guided salvage radiotherapy with lesion-directed dose escalation after radical prostatectomy: 10-year follow-up results (MRI Study: UMIN 000009823).

Kenshiro Shiraishi, Hiroshi Fukuhara, Satoru Taguchi et al. Jun 01, 2026 pp. 5115-5115 10.1200/jco.2026.44.16_suppl.5115

5115 Background: Salvage radiotherapy (SRT) after radical prostatectomy (RP) has traditionally been delivered as uniform d...

Zidesamtinib efficacy and safety in patients with advanced <i>ROS1</i> -positive solid tumors other than NSCLC in the ARROS-1 study.

Benjamin J. Solomon, Sanjay Popat, Enriqueta Felip et al. Jun 01, 2026 pp. 3108-3108 10.1200/jco.2026.44.16_suppl.3108

3108 Background: ROS1 fusions are oncogenic drivers in various cancers. Multiple ROS1 tyrosine kinase...

Diabetes risk reduction diet and mortality outcomes following breast cancer diagnosis in Black women.

Lawrence Deng, Bo Qin, Bena Liu et al. Jun 01, 2026 pp. 10622-10622 10.1200/jco.2026.44.16_suppl.10622

10622 Background: Black women continue to experience a ~40% higher breast cancer mortality rate than White women. Type II...

Effect of group community health worker–led advance care planning education on advance care planning documentation, satisfaction, palliative care, and hospice: Results from a randomized clinical trial.

Olivia Viruet Quintero, Madhuri Agrawal, Gerardo Villicana et al. Jun 01, 2026 pp. 1521-1521 10.1200/jco.2026.44.16_suppl.1521

1521 Background: Advance Care Planning (ACP) is recommended for all patients with cancer yet engagement remains low due to...

The bladder cancer journey: Using a social media campaign to uncover educational needs of patients' caregivers.

Jaime Symowicz, Amy Woodward Corum Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21017

e21017 Background: After a cancer diagnosis, many patients and their family members/friends turn to social media for infor...

Delayed serplulimab combined with nab-paclitaxel and epirubicin in high-risk, early HR+/HER2− breast cancer (HELEN-B 018): A multicenter, single-arm, phase 2 trial.

Hao Dai, Xianfu Sun, Ya Wei et al. Jun 01, 2026 pp. 609-609 10.1200/jco.2026.44.16_suppl.609

609 Background: Novel treatment options are needed to improve long-term outcome of high-risk early HR+/HER2− breast cancer...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page